Targeted Capture and Massively Parallel Sequencing to Identify Atypical Leukoencephalopathy in 48 Chinese Patients (P3.265)

Xiaole Wang,Fei Yin,Liwen Wu,Lifen Yang,Fang He,Jing Peng
DOI: https://doi.org/10.1212/wnl.86.16_supplement.p3.265
IF: 9.9
2016-01-01
Neurology
Abstract:Objective: To assess the utility and effectiveness of targeted capture and massively parallel sequencing technology in atypical leukoencephalopathy patients Background: Leukoencephalopathy is a disease with high clinical heterogeneity and involving in multiple genes, the etiological diagnosis of atypical leukoencephalopathy is difficult even for experienced neurologists. To help these patients make clear diagnosis, our team designed the personalized chip which contains 118 genes reported to be associated with leukoencephalopathy. Design/Methods: We performed a retrospective study. From December 2013 to June 2015, 48 patients with atypical leukoencephalopathy were recruited into our cohort according to the strict inclusion and exclusion criteria, at the same time, detail clinical and head imaging data were recorded. Then we screened for these patients using the personalized chip and made the validation among their parents using Sanger sequencing. Results: A total of 39.6[percnt] (19/48) of the patients exhibited pathogenic mutations. Including four associated with metachromatic leukodystrophy, three associated with vanishing white matter leukoencephalopathy, three associated with mitochondrial complex enzyme I deficiency, one associated with Krabbe disease, two associated with megalencephalic leukoencephalopathy with subcortical cysts, two associated with Pelizaeus-Merzbacher disease, one associated with X-linked adrenoleukodystrophy, one associated with Zegwell syndrome, one associated with amyotrophic lateral sclerosis and one associated with Alexander disease. In this study, fifteen pathogenic mutation sites were identified for the first time. Conclusions: These data supported the combination of targeted capture and massively parallel sequencing technology with clinical and genetic diagnosis, allowing the identification of atypical leukoencephalopathy, highlighting its usefulness for rapid and comprehensive genetic testing in the clinical. Our study reflects the incidence of leukoencephalopathy in south China, it also expand our knowledge of the genetic and clinical spectra of leukoencephalopathy. Study Supported by: NSFC :81371434, 81171226; Science and technology plan of Hunan province: 2011FJ3163 and MyGenostics Inc. Disclosure: Dr. Wang has nothing to disclose. Dr. Yin has nothing to disclose. Dr. Wu has nothing to disclose. Dr. Yang has nothing to disclose. Dr. He has nothing to disclose. Dr. Peng has nothing to disclose.
What problem does this paper attempt to address?